Tiepeng Li

747 total citations
37 papers, 428 citations indexed

About

Tiepeng Li is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tiepeng Li has authored 37 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tiepeng Li's work include Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (11 papers) and Immune Cell Function and Interaction (10 papers). Tiepeng Li is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (11 papers) and Immune Cell Function and Interaction (10 papers). Tiepeng Li collaborates with scholars based in China, United States and South Korea. Tiepeng Li's co-authors include Quanli Gao, Lingdi Zhao, Peng Qin, Yonghao Yang, Lu Han, Benling Xu, Long Yuan, Weijia Fang, Kangdong Liu and Ning Huang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biochemistry.

In The Last Decade

Tiepeng Li

34 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tiepeng Li China 11 219 149 129 85 55 37 428
Snahlata Singh India 11 205 0.9× 246 1.7× 103 0.8× 148 1.7× 50 0.9× 14 468
Chongyi Jiang China 11 129 0.6× 118 0.8× 93 0.7× 85 1.0× 80 1.5× 26 377
Koji Fujieda Japan 3 269 1.2× 77 0.5× 209 1.6× 47 0.6× 48 0.9× 3 403
Peifen Fu China 9 214 1.0× 135 0.9× 93 0.7× 97 1.1× 45 0.8× 19 390
Wenzhou Ding China 8 143 0.7× 183 1.2× 67 0.5× 182 2.1× 29 0.5× 22 403
Don Milliken United Kingdom 6 288 1.3× 97 0.7× 247 1.9× 46 0.5× 13 0.2× 12 475
Jieying Yang China 11 63 0.3× 174 1.2× 99 0.8× 113 1.3× 40 0.7× 11 318
Shikai Zhu China 14 159 0.7× 341 2.3× 59 0.5× 211 2.5× 81 1.5× 30 546
Liaoran Niu China 11 100 0.5× 157 1.1× 42 0.3× 98 1.2× 71 1.3× 30 325
Judit López‐Luque Spain 8 95 0.4× 179 1.2× 80 0.6× 70 0.8× 56 1.0× 8 368

Countries citing papers authored by Tiepeng Li

Since Specialization
Citations

This map shows the geographic impact of Tiepeng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiepeng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiepeng Li more than expected).

Fields of papers citing papers by Tiepeng Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiepeng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiepeng Li. The network helps show where Tiepeng Li may publish in the future.

Co-authorship network of co-authors of Tiepeng Li

This figure shows the co-authorship network connecting the top 25 collaborators of Tiepeng Li. A scholar is included among the top collaborators of Tiepeng Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiepeng Li. Tiepeng Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Yong, Chaoji Zhang, Peng Qin, et al.. (2025). Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy. Scientific Reports. 15(1). 28995–28995. 1 indexed citations
2.
Hu, Hui-Hui, Huifang Lv, Jianzheng Wang, et al.. (2025). Resibufogenin and Oxaliplatin Synergistically Inhibit Diffuse Gastric Cancer by Inactivating the FAK/AKT/GSK3β/β-Catenin Signaling Pathway. Recent Patents on Anti-Cancer Drug Discovery. 21(1). 14–30.
3.
Fu, Xiaomin, et al.. (2024). Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer. SHILAP Revista de lepidopterología. 3(6). e155–e155. 2 indexed citations
4.
Gong, Hui, Tingting Zhao, Honghan Chen, et al.. (2024). AMPK‐upregulated microRNA‐708 plays as a suppressor of cellular senescence and aging via downregulating disabled‐2 and mTORC1 activation. SHILAP Revista de lepidopterología. 5(3). e475–e475. 4 indexed citations
5.
Yang, Ming, Tiepeng Li, Shujin Guo, et al.. (2024). CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology. Journal of Translational Medicine. 22(1). 50–50. 6 indexed citations
6.
Long, Yuan, Yong Zhang, Tiepeng Li, et al.. (2024). Transient-resting culture after activation enhances the generation of CD8+ stem cell-like memory T cells from peripheral blood mononuclear cells. Translational Oncology. 50. 102138–102138. 1 indexed citations
7.
Li, Sen, Ké Li, Hongle Li, et al.. (2023). A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. Frontiers in Immunology. 13. 1056144–1056144. 12 indexed citations
8.
Fu, Xiaomin, Peng Qin, Yong Zhang, et al.. (2023). The inter-link of ageing, cancer and immunity: findings from real-world retrospective study. Immunity & Ageing. 20(1). 75–75. 9 indexed citations
9.
Fu, Qiang, Lingdi Zhao, Xiaomin Fu, et al.. (2022). Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. The Oncologist. 27(6). e463–e470. 9 indexed citations
10.
11.
Peng, Ling, Bicheng Zhang, Brian G. Till, et al.. (2022). Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Frontiers in Immunology. 13. 882172–882172. 4 indexed citations
12.
Chen, Honghan, Ning Huang, Hui Gong, et al.. (2022). Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling. Biochemical Pharmacology. 200. 115045–115045. 12 indexed citations
13.
Gong, Hui, Honghan Chen, Peng Xiao, et al.. (2022). miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD+/SIRT inactivation. Signal Transduction and Targeted Therapy. 7(1). 66–66. 60 indexed citations
14.
Li, Tiepeng, et al.. (2021). Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Frontiers in Pharmacology. 12. 698447–698447.
15.
Yang, Yonghao, et al.. (2021). Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. Frontiers in Immunology. 12. 728750–728750. 4 indexed citations
16.
Zhao, Lingdi, et al.. (2020). Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Frontiers in Oncology. 10. 507–507. 3 indexed citations
17.
18.
Jiang, Yanan, Jimin Zhao, Ke Li, et al.. (2018). Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. Journal of Translational Medicine. 16(1). 138–138. 25 indexed citations
19.
Zhang, Fang, Tiepeng Li, Lu Han, et al.. (2018). TGFβ1-induced down-regulation of microRNA-138 contributes to epithelial-mesenchymal transition in primary lung cancer cells. Biochemical and Biophysical Research Communications. 496(4). 1169–1175. 21 indexed citations
20.
Li, Tiepeng, Zhixin Wang, Yun Zhao, et al.. (2013). Checkpoint protein Rad9 plays an important role in nucleotide excision repair. DNA repair. 12(4). 284–292. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Snahlata Singh Breakdown of academic impact, for papers by Chongyi Jiang Breakdown of academic impact, for papers by Koji Fujieda Breakdown of academic impact, for papers by Peifen Fu Breakdown of academic impact, for papers by Wenzhou Ding Breakdown of academic impact, for papers by Don Milliken Breakdown of academic impact, for papers by Jieying Yang Breakdown of academic impact, for papers by Shikai Zhu Breakdown of academic impact, for papers by Liaoran Niu Breakdown of academic impact, for papers by Judit López‐Luque
Rankless by CCL
2026